Coverage: Don't Expect Coverage For DNA Stool Tests

Why This Topic Matters

The article helps readers understand a Medicare coverage update and avoid confusion when reporting colorectal cancer screening stool tests under CPT. It is relevant because it highlights how coding references, payer policy, and modifier use can affect claims processing.

Article Sections

1. CMS coverage decision on DNA stool tests

   Summarizes the CMS memorandum addressing coverage status for DNA-based stool screening tests and the broader policy context around their review.

2. FOBT reporting and CPT code changes

   Reviews the article’s discussion of fecal occult blood testing, including CPT code updates and the distinction between screening and diagnostic reporting.

3. CLIA-waived status and modifier guidance

   Covers the article’s discussion of laboratory status and the reporting considerations tied to that status under Medicare guidance.